Hpv-relatedness Definitions For Classifying Hpv-related Oropharyngeal Cancer Patient Do Impact On Tnm Classification And Patients' Survival by Taberna, Miren et al.
RESEARCH ARTICLE
HPV-relatedness definitions for classifying
HPV-related oropharyngeal cancer patient do
impact on TNM classification and patients’
survival
Miren Taberna1,2,3*, Marisa Mena2,4, Sara Tous2,4, Miquel Angel Pavón2,5, Marc Oliva1,
Xavier León6,7, Jacinto Garcia6, Marta Guix8,9, Rafael Hijano10, Teresa Bonfill11,
Antón Aguilà12, Laia Alemany2,5, Ricard Mesı́a3,13
1 Department of Medical Oncology, Catalan Institute of Oncology (ICO), ONCOBELL, IDIBELL, L’Hospitalet
de Llobregat, Barcelona, Spain, 2 Cancer Epidemiology Research Program, Catalan Institute of Oncology
(ICO), IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain, 3 University of Barcelona, Barcelona, Spain,
4 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain, 5 Centro de
Investigación Biomédica en Red de Cáncer (CIBERESP), Madrid, Spain, 6 Department of
Otorhinolaryngology, Hospital de Sant Pau, Barcelona, Spain, 7 Centro de Investigación Biomédica en Red
de Bioingenierı́a, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain, 8 Cancer Research Program,
IMIM, Hospital del Mar, Barcelona, Spain, 9 Department of Medical Oncology, Hospital del Mar, Barcelona,
Spain, 10 Department of Otorhinolaryngology, Hospital del Mar, Barcelona, Spain, 11 Department of Medical
Oncology, Hospital Universitari Parc Taulı́, Sabadell, Barcelona, Spain, 12 Department of
Otorhinolaryngology, Hospital Universitari Parc Taulı́, Sabadell, Barcelona, Spain, 13 Department of Medical




Given the different nature and better outcomes of oropharyngeal carcinoma (OPC) associ-
ated with human papillomavirus (HPV) infection, a novel clinical stage classification for
HPV-related OPC has been accepted for the 8th edition AJCC TNM (ICON-S model). How-
ever, it is still unclear the HPV-relatedness definition with best diagnostic accuracy and prog-
nostic value.
Material and methods
The aim of this study was to compare different staging system models proposed for HPV-
related OPC patients: 7th edition AJCC TNM, RPA stage with non-anatomic factors (Prin-
cess Margaret), RPA with N categories for nasopharyngeal cancer (MD-Anderson) and
AHR-new (ICON-S), according to different HPV-relatedness definitions: HPV-DNA detec-
tion plus an additional positive marker (p16INK4a or HPV-mRNA), p16INK4a positivity alone or
the combination of HPV-DNA/p16INK4a positivity as diagnostic tests.
Results
A total of 788 consecutive OPC cases diagnosed from 1991 to 2013 were considered eligi-
ble for the analysis. Of these samples, 66 (8.4%) were positive for HPV-DNA and (p16INK4a
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or HPV-mRNA), 83 (10.5%) were p16INK4a positive and 58 (7.4%) were double positive for
HPV-DNA/p16INK4a. ICON-S model was the staging system, which performed better in our
series when using at least two biomarkers to define HPV-causality. When the same analysis
was performed considering only p16INK4a-positivity, RPA stage with non-anatomic factors
(Princess Margaret) has the best classification based on AIC criteria.
Conclusion
HPV-relatedness definition for classifying HPV-related OPC patient do impact on TNM clas-
sification and patients’ survival. Further studies assessing HPV-relatedness definitions are
warranted to better classify HPV-related OPC patients in the era of de-escalation clinical
trials.
Introduction
Human Papillomavirus (HPV) related oropharyngeal squamous cell carcinoma (OPC) repre-
sents a distinct entity, with different clinical, epidemiological and molecular features, treat-
ment responsiveness and survival [1]. A 58–74% reduction in the risk of death has been
observed in HPV-related OPC when compared with HPV non-related OPSCC associated to
the classical risk factors, tobacco and alcohol [2,3]. Taking into account these differences, it
became evident that the 7th edition American Joint Committee on Cancer (AJCC) TNM stag-
ing system does not reflect accurately patient survival in order to drive therapeutic decisions
for HPV-related OPC patients. This disparity in prognosis affects clinical trials design, evalua-
tion of treatment outcomes, research and communication between head and neck cancer
health community. Therefore, several approaches for HPV-OPC new staging systems have
already been proposed and one of them has been selected for the 8th edition AJCC TNM.
Importantly, OPC HPV relatedness definition is still under development and the new stag-
ing system proposals have not adhered to a strict definition of viral aetiology of OPC cases. It
is already well understood that HPV-DNA detection alone is not sufficient to classify an OPC
as HPV-related since the presence of HPV-DNA could only reflect a transient infection [4].
Additionally, the detection of p16INK4a expression is not specific for HPV activity [4,5]. The
choice of HPV-relatedness definition do impact on patients survival; p16INK4a high expression
but HPV-DNA-negative OPC patients have showed significantly less favourable survival than
patients with p16INK4a high expression and HPV-DNA-positive tumours [6].
Before the new TNM edition was accepted, several proposals were described. Huang and
colleagues [7] developed a new staging system by using a recursive partitioning analysis (RPA)
and a adjusted hazard ratio (AHR) model for overall survival (OS), comprising both anatomic
(TNM) and non-anatomic parameters such as age and tobacco. Dahlstrom and colleagues [8]
were unable to validate all the categories of this proposal so they created a new staging system
by incorporating traditional N stage categories used for nasopharyngeal cancer [8,9]. Finally,
O’Sullivan and colleagues, with The International Collaboration on Oropharyngeal cancer
Network for Staging (ICON-S) [10], validated in a new cohort the previous described RPA
and AHR systems, and finally proposed an AHR-New model for the 8th edition of the TNM
classification, which was finally accepted. Table 1 summarized the 7th edition AJCC TNM stag-
ing system, and the three main new staging systems proposals: RPA stage with non-anatomic
factors (Princess Margaret) [7], RPA with N categories for nasopharyngeal cancer (NPC)
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(MD-Anderson) [8] and AHR-new (ICON-S) [10]. Importantly, none of them used a uniform
HPV testing method to define HPV-relatedness (Table 1).
A novel clinical stage classification for HPV-related OPC has already been described for the
8th edition AJCC TNM, based on the ICON-S proposal [11] Main differences among 7th and
8th TNM editions including HPV-related oropharyngeal cancer patients are summaryzed on
Table 2.
Materials and methods
Study population and design
We carried out a retrospective study to assess the prognostic and predictive value of HPV
viral DNA and of HPV-related carcinogenic biomarkers, in formalin-fixed paraffin-embed-
ded (FFPE) samples of OPC, consecutively selected from four different hospitals from Cata-
lonia (Catalan Institute of Oncology-ICO-Hospital Universitari de Bellvitge; Hospital de
Sant Pau, Hospital del Mar and Hospital Parc Taulı́) [12] from 1991 to 2013. Nested within
this study was this sub-analysis to compare the different staging systems proposed for HPV-
related OPC patients in an independent data set with different HPV-relatedness definitions.
Cases were pathologically confirmed and metastatic patients discarded. Demographic and
clinical information was extracted from clinical reports of each center and all data was fully
anonymized. All methods were carried out in accordance with relevant guidelines and regu-
lations. The protocol was approved by the Institutional Review Broad of each participating
hospital, which required no informed consent to use archived tumor samples and retrospec-
tive data.
Table 1. Summary of 7th edition AJCC TNM and new staging system proposals.
Staging System N HPV-relatedness definition New proposal Stage Classifications 5 years OS by
Stage
7th edition AJCC TNM [11] NA NA NA Stage I (T1N0) NA
Stage II (T2N0)
Stage III (T3N0 or T1-T3N1)
Stage IVa (T4aN0-1 or
T1-T4aN2)
Stage IVb (T4b or T1-T4bN3)
Princess Margaret Huang et al.
[7]
573 p16INK4a IHC RPA stage with non-anatomic
factors
RPA-I (T1-3N0-N2c 20 PY) RPA-I: 89%
RPA-II (T1-3N0-N2c >20 PY) RPA-II: 64%
RPA-III (T4 or N3_age 70) RPA-III: 57%
RPA-IVA (T4 or N3_age >70) RPA-IVA: 40%
MD Anderson Dahlstrom et al.
[8]
661 HPV-DNA ISH or p16INK4a IHC or
both
RPA with N categories for NPC Stage IA (T1N0-N2) IA: 94%
Stage IB (T2N0-N2) IB: 87%
Stage II (T1-T2N3 or
T3N0-N3)
II: 76%
Stage III (T4) III: 69%
ICON-S O’Sullivan et al. [11] 1907 HPV-DNA ISH or p16INK4a IHC AHR-New (ICON-S) Stage I (T1-T2N0-N1) I: 88%
Stage II (T1-T2N2 or
T3N0-N2)
II: 81%
Stage III (T4 or N3) III: 65%
NA: Not applicable; IHC: immunohistochemistry; ISH: in situ hybridization; OS: Overall survival; RPA: recursive partitioning analysis; PY: Pack-years; NPC:
nasopharyngeal cancer; ICON-S: The International Collaboration on Oropharyngeal Cancer Network for Staging; AHR: adjusted hazard ratios.
https://doi.org/10.1371/journal.pone.0194107.t001
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Histopathological evaluation and laboratory analysis
All determinations were centrally performed in FFPE at the Catalan Institute of Oncology, the
detailed methods used for immunohistochemistry (IHC), HPV-DNA detection, genotyping,
and HPV E6I mRNA performance have been reported elsewhere [13]. Hematoxylin and
eosin stained slides were used to confirm presence and estimate the proportion of invasive
SCC in the specimen as well as to classify histopathological features. Briefly, we used Roche
mtm Laboratories AG IHC (Heidelberg) for p16INK4a determination and SPF-10 polymerase
chain reaction (PCR) and a DNA enzyme immunoassay (DEIA) to test for the presence of
HPV-DNA in all cases. Genotyping was performed using reverse hybridization line probe
assay (LiPA25_v1). All samples testing positive for HPV-DNA underwent E6I mRNA detec-
tion at DKFZ, Heidelberg, Germany, as developed by Halec and colleagues [14]. p16INK4a IHC
was considered positive when the pattern showed a strong and diffuse nuclear and cytoplasmic
staining in at least 70% of the tumor [15].
We used different definitions for HPV-positivity to evaluate the staging system proposals.
Firstly, cases were stratified by tumor HPV status and were considered HPV-related if
HPV-DNA PCR and (p16INK4a IHC or HPV-mRNA PCR) determination were positive. Sec-
ondly, cases were analyzed by p16INK4a IHC expression alone, as p16INK4a is widely used in
clinical settings and some of the staging system proposals evaluated in this study use only this
biomarker to define HPV-positivity. Finally, cases were defined as HPV-positive when both
HPV-DNA and p16INK4a expression remained positive, as this combination has been shown to
Table 2. Main differences among 7th and 8th TNM editions including HPV-related oropharyngeal cancer patients. Modified from Taberna et al. Annals of Oncology
2017 [1].
Characteristics 7th Edition TNM 8th Edition TNM ICON-S
Stage Classifications -Stage I (T1N0) -Stage I (T1-T2N0-N1)
-Stage II (T2N0) -Stage II (T1-T2N2 or T3N0-N2)
-Stage III (T3N0 or T1-T3N1) -Stage III (T4 or N3)
-Stage IVa (T4aN0-1 or T1-T4aN2) -Stage IV (M1)
-Stage IVb (T4b or T1-T4bN3)
-Stage IVc (M1)
Main N (lymph node)
differences
-N1: metastasis in a single ipsilateral lymph nodes, < 3 cm -N1: ipsilateral metastasis in lymph node(s), < 6 cm
-N2a: metastasis in a single ipsilateral lymph node > 3 cm
but < 6 cm.
-N2: bilateral or contralateral metastasis in lymph node(s), < 6 cm
-N2b: metastasis in multiple ipsilateral lymph nodes, < 6
cm




T4a: Tumor invades the larynx, extrinsic muscle of tongue,
medial pterygoid, hard palate or mandible
T4: Tumor invades any of the following: larynx, deep/extrinsic muscle of
tongue, medial pterygoid, hard palate, mandible, lateral pterygoid muscle,
pterygoid plates, lateral nasopharynx, skull base or encases carotid artery T4b: Tumor invades lateral pterygoid muscle, pterygoid
plates, lateral nasopharynx, skull base or encases carotid
artery
HPV: Human papillomavirus; OPSCC: Oropharyngeal squamous cell carcinoma; NA: Not applicable; OS: Overall survival; ICON-S: The International Collaboration on
Oropharyngeal cancer Network for Staging; T: tumor; N: lymph node; M: metastasis
 Because 5-years OS was similar among N1, N2a and N2b, they re-termed the N categories.
 Because 5-years OS was similar among T4a and T4b, they were no longer subdivided and it was re-termed as T4.
To better understand and compare the different staging systems proposed and the accepted one, we have validated them in an independent data set, with different HPV-
relatedness definitions.
https://doi.org/10.1371/journal.pone.0194107.t002
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have highest specificity to describe HPV-transformed OPCs [16] and its implementation in
the clinical setting is easier compared to mRNA HPV detection.
Statistical considerations
We estimated the rates of OS by means of the Kaplan–Meier method. Due to the low number
of cases, Nelson-Aalen estimates of the OS were also performed without observing statistically
significant differences between the two methods. We used log-rank test to evaluate the equality
of survivor functions across two or more groups and a univariate Cox model (proportional
hazard model) was also performed for each stage classification. Trend test was used to evaluate
the trend of the survival function across the three or more ordered groups. The comparison of
these models was done using AIC (Akaike Information Criterion) which estimate the quality
of each model, relative to each of the other models; these criteria penalize the number of
parameters in the model selecting the one with the lowest AIC as the best model.
Results
A total of 788 consecutive OPC cases diagnosed from 1991 to 2013 were obtained and consid-
ered eligible for the analysis. Of these samples, 66 (8.4%) were HPV-related (HPV-DNA PCR
and (p16INK4a IHC or HPV-mRNA PCR) positive) and had a non-metastatic stage. Of note, all
samples double positive for HPV DNA and p16 INK4a IHC were also positive for HPV-mRNA.
The demographic and clinical characteristics of the 66 HPV-related non-metastatic OPC
evaluable cases are shown in Table 3. HPV-related OPC patients had a mean age of 60.2 (SD:
13.8), 45 were male (68.2%), 34 were smokers (51.5%); 55 were diagnosed during the period
of 2000–2013 (83.3%) and the tonsil was the most common subsite (45, 68.2%). The majority
of patients (48, 72.7%) were treated with chemo(radiotherapy) and only 16 (24.2%) underwent
a primary surgery procedure. After a median follow-up of 5.0 years (Range: 0.2–22.7), 44
(66.7%) patients were still alive.
We performed the comparison among the 7th AJCC TNM edition and the different staging
systems proposed for HPV-related OPC patients based on three different HPV-relatedness
definitions. Fig 1 shows the Kaplan-Meier estimates of 5-years OS and the Trend test resulted
according to each staging system, for HPV-DNA PCR and (p16INK4a IHC or HPV-mRNA
PCR) positive cases. Following the AIC criteria for models comparison, we observed that all
the staging classifications improved the OS assessment in HPV-related OPC patients com-
pared with the 7th edition AJCC TNM classification (Table 4). P-trend test was statistically sig-
nificant for all the new proposal staging systems and non-significant for the 7th edition AJCC
TNM staging system (P = .685). Based in our series, the best classification was AHR-new
(ICON-S) (P = .05; AIC: 117.5; Trend test P = .02), followed by RPA with N categories for
NPC (MD-Anderson) and RPA stage with non-anatomic factors (smoking and age) (Princess
Margaret).
The same analysis was performed taking into account only p16INK4a-positivity (N = 83), as
it is the regular technique use in the clinical setting. Fig 2 shows the Kaplan-Meier estimates of
5-years OS and the Trend test result according to each staging system. Differently from the
previous analysis, RPA stage with non-anatomic factors (Princess Margaret) has the best classi-
fication based on AIC criteria (P = .02; AIC: 202.6; Trend test P = .01), followed by AHR-new
(ICON-s) and RPA with N categories for NPC (MD-Anderson).
Finally, we performed the analysis using the combination of HPV-DNA and p16INK4a posi-
tivity (N = 58). Kaplan-Meier estimates of 5-years OS and the Trend test are represented on
Fig 3. The best classification taking into account the AIC model was again the AHR-new
HPV-relatedness definition for oropharyngeal cancer patients AND TNM classification
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(ICON-S) (P = .04; AIC: 74.8; Trend test P = .04), followed by RPA with N categories for NPC
(MD-Anderson).
Results from HPV-related OPC patients’, p16INK4a-positive patients’ and the double positiv-
ity for HPV-DNA/p16INK4a patients’ analysis are summarized on Table 4.
Discussion
To our knowledge, this is the first attempt to validate the different staging systems proposed
for HPV-related OPC patients, in an independent data set using different HPV-relatedness
definition to determine HPV-causality.
We observed that all the staging classifications proposed improve the overall survival assess-
ment in HPV-related OPC patients compared with the current 7th edition AJCC TNM classifi-
cation independent of the HPV-relatedness definition. ICON-S model proposed by O’Sullivan
and colleagues has been accepted for the 8th edition AJCC TNM [10]. In accordance with it,
ICON-S model was the staging system which performed better in our series when using at
least two biomarkers to define HPV-causality (HPV-DNA and (p16INK4a or HPV-mRNA) or
double positivity for HPV-DNA/p16INK4a). Nevertheless, this result was not reached when
HPV-positive patients were defined based on p16INK4a expression alone. In this scenario,
Table 3. Demographic and clinical characteristics of the 66 HPV-related non-metastatic OPC included on the
analysis.
Characteristic HPV/DNA+ AND (HPV-mRNA+ OR p16INK4a+) (N = 66)
N %









Non Smoker 32 48.5
20 PY 14 21.2
>20 PY 20 30.3
Alcohol status
Non Drinker 36 54.5
Moderate (100 g/d) 24 36.4
Heavy (> 100g/d) 20 9.1
Subsite
Tonsil 45 68.2






HPV: Human papillomavirus; OPC: Oropharyngeal squamous cell carcinoma; SD: Standard deviation; NA: not
applicable; PY: pack-year; g/d: grams per day; RT: Radiotherapy; CT: Chemotherapy.
https://doi.org/10.1371/journal.pone.0194107.t003
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Princess Margaret model was the sating system which performed better following the AIC cri-
teria. This finding, suggest that HPV-relatedness definitions for classifying HPV-related OPC
patients do impact in OS and TNM classifications. It is important to mention that none of the
three new staging system evaluated used in their criteria an uniform test with at least two bio-
markers (i.e. p16INK4a/HPV-DNA positivity) to define an HPV-related OPC patient. As we
have demonstrated in a previous publication carried out by our group [13], using either or
both E6I mRNA or p16INK4a in addition to HPV-DNA is a good combination for HPV-cau-
sality detection in OPC, as detection of HPV-DNA alone is not sufficient to establish causality
and using p16INK4a IHC alone is questionable, because a subset of HPV-DNA and mRNA neg-
ative OPCs show diffuse p16INK4a staining, indicating expression is not specific for HPV activ-
ity and maybe over-expressed by another cause (for example, a Rb mutation). The discordant
Fig 1. Kaplan-Maier estimates of Overall Survival among the 66 HPV-related OPSCC patients, according to each staging system. Data on 5-years Overall Survival
and Trend test are shown according to each staging system for HPV-related OPSCC patient. Panel A showed Kaplan-Meier curve for the 7th edition AJCC TNM
classification with a non-statistically significant Trend test P-value. Panel B showed Kaplan-Meier curve for RPA stage with non-anatomic factors (Princess Margaret).
Panel C showed Kaplan-Meier curve for RPA with N categories for nasopharyngeal cancer (MD-Anderson). Panel D showed Kaplan-Meier curve for AHR-new
(ICON-S). For Panel B, C and D Trend tests were statistically significant, indicating that the trend of the survival function across the three or more stages classifies
them in a linear tendency. Panel D, AHR-new (ICON-S), has the best classification based on AIC criteria.
https://doi.org/10.1371/journal.pone.0194107.g001
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rates are around 20% of the cases [17], being mostly p16INK4a-positive and HPV-DNA-nega-
tive cases. On the other hand, HPV-mRNA detection is difficult to reproduce on the clinical
setting, therefore the combination of p16INK4a IHC and HPV-DNA detection (by PCR or ISH)
has been studied. A recent meta-analysis showed that this combination is the method with the
highest accuracy to diagnose HPV-related OPCs [16]. Importantly, Rietbergen et colleagues
demonstrated, that patients with p16INK4a-positive but HPV-DNA-negative OPC showed a
significantly less favourable survival than patients with p16INK4a-positive and HPV-DNA-posi-
tive tumors (P<0.001) [6]. We have recently validated these data on an independent series
[12], indicating that p16INK4a expression alone is not an appropriate diagnosis and prognosis
biomarker for an accurate HPV-relatedness definition. In line with our results, data from a
recent report by Nauta and colleagues evaluating the 8th TNM classification on p16 INK4a-posi-
tive OPC in Netherlands, highlight the importance to perform additional HPV DNA-testing
when predicting OPC patients prognosis [18]. Moreover, Boscolo-Rizzo and colleagues have
also defended the use of more accurate biomarkers beside p16INK4a expression alone to classify
HPV-related OPC patients [19]. As these authors explained in a recent article, the attributable
fraction of HPV-related OPC variate geographically, assuming that p16INK4a sensitivity and
specificity are the same in all regions (high versus low attributable fractions), its diagnostic
positive predictive value will drop considerably if the a priori probability of having a HPV-
positive OPSCC is lowered [19]. This information is extremely important in order to classify
accurately HPV-related OPC patients within the TNM staging system. In an era where de-
escalation clinical trials evaluating surgical and conservative treatments are under develop-
ment, an OPC patient’ misclassification could seriously affect their quality of life and survival.
Table 4. HPV-related OPC patients classify by AIC criteria and Trend tests results according to each HPV-relatedness definition.
HPV-DNA and (p16INK4a or HPV-mRNA) positive patients (N = 66)
TNM classification Log-likelihood ratio test P-value Trend test P-value AIC Conclusion
7th edition AJCC TNM 0.4655 0.6859 124.08 Worse than the null model
Princess Margaret 0.0535 0.0081 118.00
MD Anderson 0.0510 0.0144 117.89
ICON-S 0.0467 0.0166 117.53 Best AIC model
Null model 119.66
p16INK4a-positive patients (N = 83)
TNM classification Log-likelihood ratio test P-value Trend test P-value AIC Conclusion
7th edition AJCC TNM 0.7919 0.4243 221.29 Worse than the null model
Princess Margaret 0.0222 0.0121 202.56 Best AIC model
MD Anderson 0.2102 0.0615 216.46 Worse than the null model
ICON-S 0.0211 0.0207 211.27
Null model 214.99
HPV-DNA and p16INK4a positive patients (N = 58)
TNM classification Log-likelihood ratio test P-value Trend test P-value AIC Conclusion
7th edition AJCC TNM 0.6801 0.2096 83.01 Worse than the null model
Princess Margaret 0.4171 0.2041 80.47 Worse than the null model
MD Anderson 0.1280 0.0427 77.62 Worse than the null model
ICON-S 0.0393 0.0371 74.84 Best AIC model
Null model 77.31
HPV: Human papillomavirus; OPC: Oropharyngeal squamous cell carcinoma; AIC: Akaike Information Criterion; ICON-S: International collaboration on
oropharyngeal cancer network for staging
https://doi.org/10.1371/journal.pone.0194107.t004
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Noteworthy, recent results from the ECOG-1308, the first de-escalation clinical trial for
HPV-related OPC published [20] have demonstrated that clinical complete response to induc-
tion chemotherapy could select patients for reduced-dose IMRT (54 Gy) in combination with
cetuximab with 2-years progression free survival (PFS) of 80% and significant improved swal-
lowing and nutritional status. Importantly in this study, all treatment failures were among
patients with a >10 PY smoking history, and in a post hoc analysis 2-years PFS was signifi-
cantly higher among patients with 10 PY compared with dose with>10 PY (92% v %7%;
P = .0014). Importantly, tobacco use seems to be diverse in North America with respect to
Europe. Therefore, different risk factor exposure may contribute to a combined risk situations
[19] according to the intermediate and high risk profile defined as previously by Ang and col-
leagues [2]. Despite ICON-S model was the staging system which performed better in our
Fig 2. Kaplan-Maier estimates of Overall Survival among the 83 p16INK4a-positive patients, according to each staging system. Data on 5-years Overall Survival
and Trend test are shown according to each staging system for HPV-related OPSCC patient. Panel A showed Kaplan-Meier curve for the 7th edition AJCC TNM
classification with a non-statistically significant Trend test p-value. Panel B showed Kaplan-Meier curve for RPA stage with non-anatomic factors (Princess Margaret).
Panel C showed Kaplan-Meier curve for RPA with N categories for nasopharyngeal cancer (MD-Anderson). Panel D showed Kaplan-Meier curve for AHR-new
(ICON-S). For Panel B and D Trend tests were statistically significant, indicating that the trend of the survival function across the three or more stages classifies them
in a linear tendency. Panel B, RPA stage with non-anatomic factors (Princess Margaret), has the best classification based on AIC criteria.
https://doi.org/10.1371/journal.pone.0194107.g002
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series, adding non-anatomic factors for the TNM staging system should be further considered,
as it has been suggested by other groups before [9].
The strength of the present study is to evaluate the different staging systems proposed for
HPV-related OPC patients, in an independent data set with different HPV-relatedness defini-
tions. Nevertheless, the most important limitation is the low rate of HPV-positive OPC
patients included in the analysis, since HPV-related OPC attributable fraction in our country
is still low in comparison with other geographic regions like US or North Europe.
A novel clinical stage classification for HPV-related OPC has already been described for the
8th edition AJCC TNM. Nevertheless, further studies about HPV-relatedness definitions are
warranted in larger series of cases to better classify HPV-related OPC patients in an era of de-
escalation clinical trials.
Fig 3. Kaplan-Maier estimates of Overall Survival among the 58 HPV-DNA/p16INK4a double positive patients, according to each staging system. Data on 5-years
Overall Survival and Trend test are shown according to each staging system for HPV-related OPSCC patient. Panel A showed Kaplan-Meier curve for the 7th edition
AJCC TNM classification with a non-statistically significant Trend test p-value. Panel B showed Kaplan-Meier curve for RPA stage with non-anatomic factors
(Princess Margaret). Panel C showed Kaplan-Meier curve for RPA with N categories for nasopharyngeal cancer (MD-Anderson). Panel D showed Kaplan-Meier curve
for AHR-new (ICON-S). For Panel C and D Trend tests were statistically significant, indicating that the trend of the survival function across the three or more stages
classifies them in a linear tendency. Panel D, AHR-new (ICON-S), has the best classification based on AIC criteria.
https://doi.org/10.1371/journal.pone.0194107.g003
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